Dolutegravir and Risk of Neuropsychiatric Adverse Events: A Pharmacogenetic Study.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 40036182.
- Also identified by DOI 10.1093/infdis/jiaf098.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dolutegravir (DTG) treatment can lead to neuropsychiatric adverse events (NPAEs). This study assessed the association between NPAEs and polymorphisms in DTG-related pharmacogenes, determined by next-generation sequencing panel testing. Using a case-control design, 36 patients having previously discontinued DTG due to NPAEs were compared to 98 patients tolerating DTG. In the latter group, psychometric scores were compared according to genotype, targeting polymorphisms associated with drug intolerance. NR1I2 c.-22-7659C > T was independently associated with a reduced risk of NPAE-related DTG discontinuation (odds ratio, 0.36 [95% confidence interval, .15-.88] for T-variant allele carriage) and was linked to decreased anxiety scores in control group participants.
Medical subject headings
- Heterocyclic Compounds, 3-Ring
- HIV Integrase Inhibitors
- Mental Disorders